1 Fixed-combination products have several advantages over concomitant therapy.
First, they are more convenient because they are dispensed from only one bottle. In addition, fixed-combination products avoid drug washout that can occur when two drugs are administered too rapidly in succession, and they reduce patients' lifetime exposure to ocular preservatives.
The European Glaucoma Society suggests that fixed-combination products be used in place of two concomitantly administered medications whenever possible. or lactating or of childbearing potential who were not using reliable means of birth control were also excluded from the study.
Study Design
All eligible patients completed an ocular symptom survey and then received TTFC. They 
Study Endpoints
The primary efficacy variable was the mean change in IOP from the screening/baseline visit to the Week 8 visit for patients receiving prior bimatoprost/timolol fixed combination.
Results were analyzed using a paired t-test.
Assuming a standard deviation of 3 mmHg and a total of 45 evaluable patients receiving prior bimatoprost/timolol fixed combination, this study was designed to provide an 80% power to detect a 1 mmHg difference between both fixedcombination therapies.
Statistical Analysis
If both eyes of a patient qualified for the study and 
RESULTS
A total of 105 patients from nine sites throughout Germany (n=3), Spain (n=3), and the Czech Republic (n=3) were enrolled in the study and comprised the ITT population. One patient was lost to follow-up after the screening/baseline visit and was removed from further analysis.
Another patient discontinued treatment at Week 4 due to intolerance of study medication, but she remained in the ITT population and last observation carried forward was employed.
Patient demographics are shown in 
Change in IOP
In the total population, the mean reduction in 
P=0.002).

Ocular Symptom Survey
The percentage of patients who were free of specific ocular symptoms was numerically higher L i g h t s e n s i t i v i t y I n c r e a s e d t e a r i n g S t i n g i n g / b u r n i n g C r u s t i n g e y e s I t c h y e y e s S a n d y o r g r i t t y f e e l i n g i n e y e s
E y e i r r i t a t i o n E y e r e d n e s s ( j u d g e d b y p a t i e n t ) E y e r e d n e s s ( j u d g e d b y o t h e r s )
Symptom-free patients (%)
Travoprost 0.004%/ timolol 0.5%, n=103 between prior therapy and study medication were noted for the persistence of symptoms or the ease of eye drop instillation (P=0.726).
Examination of patient subgroups showed that the symptom profile of the prior fixedtherapy subgroup was similar to the symptom profile of the total patient population, but some differences were apparent in the subgroup who had previously taken unfixed bimatoprost and timolol. Specifically, severity of stinging/burning was not statistically different between TTFC and unfixed bimatoprost and timolol, but patients reported that eye redness was more frequently judged by others to be present while they had been taking the unfixed bimatoprost and timolol (P=0.041).
Patient and Investigator Preferences
Patients preferred TTFC over prior therapy at a ratio of more than 4:1 (81.4% vs. 18.6%;
P<0.001; Figure 4 
Safety
A total of 29 adverse events were reported, of which 15 were judged to be related to treatment with TTFC: ocular hyperemia, ocular burning, blurred vision, foreign body sensation, and allergic reaction ( Table 2) 
P<0.001
Global preference (%) Prefer travoprost 0.004%/ timolol 0.5% xed combination Figure 4 . Global preference response for the intent-to-treat patient population (n=102) and investigators (n=102). Table 2 . Travoprost 0.004%/timolol 0.5%-related adverse events in the intent-to-treat population (n=105). 
Adverse event Number of events
